Bio­phar­ma's Chi­na plan gets a boost from patent pro­tec­tions sealed in now of­fi­cial trade deal

As in­ter­na­tion­al re­la­tions ex­perts con­tin­ue to cast skep­ti­cism on the “phase one” US-Chi­na trade deal signed Wednes­day, multi­na­tion­al drug­mak­ers found much to be cheer­ful about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER